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Executive Summary 
In 2017, substance use cost Canadians almost $46.0 billion, led to over 275,000 hospitalizations and 
contributed to the loss of nearly 75,000 lives. This report presents the estimates of the costs of substance 
use in Canada from 2015 to 2017 using the most reliable, up-to-date data sources and methods according to 
the following categories:
• Cost type (healthcare costs, lost productivity costs, criminal justice costs and other direct costs);
• Substance (alcohol, tobacco, cannabis, opioids, other CNS depressants, cocaine, other CNS 
stimulants and other drugs)
• Province and territory
Where data were available for specific costs, costs and harms are presented by health condition, sex and 
age group. 
This report is an update to Canadian Substance Use Costs and Harms 2007–2014, released in June 2018 
(Canadian Substance Use Costs and Harms Scientific Working Group, 2018). Estimates presented in this 
report, however, should not be directly compared with estimates presented in the 2007–2014 report as we 
have improved our methods since the publication of the earlier report.
The estimates in this report give us a picture of the costs and harms associated with substance use in 
Canada. These estimates are a baseline against which to monitor the impacts of current and future policies 
related to substance use in Canada. Impacts include the effects of cannabis legalization, outcomes of the 
opioid crisis, and the likely major impact of the COVID-19 pandemic on patterns of substance use, costs  
and harms. 
The ability to track costs and trends in harms uniquely caused by specific types of substances is valuable to 
governments, businesses, and advocacy groups working to reduce these harms. A better understanding of 
the societal costs associated with different substances can help inform policy decision making and resource 
allocation for law enforcement, prevention, treatment and harm reduction services.
Overall Costs of Substance Use
In 2017: 
• Almost 63% of the total costs of substance use were due to alcohol and tobacco. 
• The four substances associated with the largest costs were (in order):
• Alcohol, accounting for $16.6 billion or 36.2% of the total costs;
• Tobacco, accounting for $12.3 billion or 26.7% of the total costs;
• Opioids, accounting for $5.9 billion or 12.9% of the total costs; and 
• Cocaine, accounting for $3.7 billion or 8.1% of the total costs. 
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Between 2015 and 2017,1, the per-person2 cost of substance use (SU) increased 3.3% in real terms from 
$1,218 in 2015 to approximately $1,258 in 2017. However, the per-person costs varied significantly among the 
substances assessed. The four substances for which per-person costs increased the most (in order) between 
2015 and 2017 were: 
• Central nervous system (CNS) stimulants, (including amphetamines and methamphetamine, but 
excluding cocaine), the costs of which increased 22.1% from $44 to $54;
• Opioids, the costs of which increased 20.9% from $135 to $163;
• Cocaine, the costs of which increased 10.5% from $92 to $102; and
• Alcohol, the costs of which increased 1.6% from $448 to $455. 
In contrast to these increases, between 2015 and 2017 the per-person cost of tobacco use decreased by 
5.1% ($354 to $336). In 2015, alcohol and tobacco use combined accounted for 65.8% of the total per-person 
cost of SU in Canada. In 2017, the costs associated with using these substances decreased to 62.9% of the 
total per-person cost.
Healthcare Costs
Healthcare costs include inpatient hospitalizations, day surgeries, emergency department visits, specialized 
treatment3 for SU disorders, physician time and prescription drugs. 
In 2017:
• Healthcare costs related to SU were $13.1 billion (28.4% of the total cost of SU) or $386 per person in 
Canada.4 Of these costs, inpatient hospitalizations accounted for 24.5%, physician time accounted for 
37.4% and prescription drugs accounted for 28.5%. 
• Alcohol ($5.4 billion) and tobacco ($6.1 billion) contributed almost 89% of costs. 
• After alcohol and tobacco, the use of opioids cost the healthcare system the third-highest amount at 
$439 million (3.4%). 
• Contributing to these costs were 277,060 SU-attributable hospitalizations of which 141,271 (51.0%) 
were attributable to tobacco use and 105,065 (37.9%) to alcohol use.
• Per-person healthcare costs related to SU were highest in the territories. This finding reflects higher 
rates of alcohol and tobacco use in the territories, and high costs associated with health care for 
territorial residents.
1 Throughout this report, costs for all years are presented in 2017 Canadian dollars.
2 Per-person estimates in this report do not include costs associated with inpatient hospitalizations, day surgeries or emergency 
department visits in Quebec. This likely led to an underestimation of about $857 million or 1.9% of total costs. The 2017 per-person 
estimates do not include costs associated with lost productivity due to premature deaths in Yukon, as these data were not available 
from Statistics Canada’s Vital Statistics database at the time of this report. This likely led to an underestimation of approximately 
$103 million or 0.2% of total costs. All estimates are likely conservative by about $960 million or 2.1%.
3 Specialized treatment refers to psychosocial services for substance use only, recognizing that these services are one form of 
treatment within a larger healthcare system. For details on what this treatment includes, see the technical report.
4 Only some healthcare-related data were available for Quebec. This per-person healthcare cost does not include the costs or 
population of Quebec.
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Between 2015 and 2017, per-person healthcare costs associated with any SU increased 2.7% from $348 to 
$358.5 Per-person healthcare costs associated with individual substances also increased as follows:
• Alcohol increased 4.8% from $142 to $149.
• Cannabis increased 20.8% from $7 to $9. 
• Opioids increased 11.5% from $11 to $12.
• CNS stimulants (excluding cocaine) costs increased 37.3% from $5 to $7.  
Lost Productivity Costs
Cost estimates of SU-attributable lost productivity were based on the lost value of work due to premature 
death, long-term disability and short-term disability (absenteeism and impaired job performance).
In 2017:
• Lost productivity costs attributable to SU in 2017 were $20.0 billion or $548 per person.
• Costs associated with the use of alcohol and tobacco were estimated to account for just 
over 63% of all lost productivity costs associated with SU.
• Contributing to these costs were 23,792 SU-attributable deaths among Canadians under 
65 years old and 338,555 potential years of productive life lost. Alcohol use was found to 
be the leading cause of SU-attributable lost productivity.
Between 2015 and 2017:
• Overall per-person lost productivity costs increased about 4.5% from $524 in 2015 to $548 in 2017. 
• The largest increase in per-person lost productivity costs was associated with opioid use. These 
costs increased 34.1% from $87 per person in 2015 to $116 per person in 2017. This increase is 
due to the rising number of premature deaths related to opioid use during this period. 
• The number of premature deaths related to opioid use increased by 32.8%, from 3,829 to 5,084.
Criminal Justice Costs
Criminal justice costs include costs associated with policing, courts and correctional services 
(admissions to sentenced custody). Our calculations include expenditures for:
• Crimes that are 100% attributable to SU. These refer to impaired driving and drug-related 
offences that fall under the Controlled Drugs and Substances Act; and
• Crimes that are partially attributable to SU. These refer to violent crimes such as homicide or 
assault, and non-violent crimes such as theft or arson.
In 2017:
• Over $9.2 billion was spent on criminal justice costs associated with SU, which amounts to 
$253 for every Canadian. 
• Forty-two percent of crimes (excluding impaired driving and crimes defined under the 
Controlled Drugs and Substances Act) would not have occurred if the perpetrator had not 
been under the influence of, or seeking, alcohol or other drugs. 
5 Only some healthcare data were available for Quebec. These national per-person trend estimates include the costs and population 
of Quebec and therefore differ from the $386 indicated above.
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• Almost 20% of all violent crimes were associated with alcohol use alone. 
• Alcohol use accounted for the greatest costs to the criminal justice system at $2.8 billion or 
30.2% of all criminal justice costs.
• Cocaine use accounted for the second-highest criminal justice costs related to SU ($2.6 billion 
or 27.8%). Only 8.0% of this cost was associated with violations of the Controlled Drugs and 
Substances Act (e.g., trafficking, possession). The other 92.0% was associated with other violent 
and non-violent crimes. 
• Cannabis use accounted for the third-highest criminal justice costs related to SU ($1.6 billion or 
17.5%). Forty percent of these costs were a direct result of this substance’s illegality; the costs 
are for policing, court and correctional services associated with manufacturing, trafficking and 
possession. Cannabis use for non-medical purposes was not yet legal in Canada in 2017. 
Between 2015 and 2017: 
• Criminal justice costs increased 1.1% from $250 per person in 2015 to about $253 per person in 2017. 
• Criminal justice costs associated with cocaine increased 6.8% from $66 to $70 per person.
• Criminal justice costs associated with CNS stimulants increased 18.5% from $18 to $22 per person.
• Criminal justice costs associated with alcohol decreased 2.7% from $79 to $76 per person.
• Costs associated with cannabis decreased 3.4% from $46 to $44 per person.
Other Direct Costs
Other direct costs related to SU include costs across several categories, including research and prevention, 
fire damage, damage to motor vehicles and workplace costs not already covered in lost productivity (e.g., 
employee assistance programs, drug testing programs and administrative costs associated with workers’ 
compensation).
In 2017:
• These other direct costs contributed over $3.6 billion, the equivalent of $100 per Canadian, to 
the total cost related to SU. 
• Alcohol use accounted for 45.5% of other direct costs, followed by cannabis use at 21.6%.
• Over $2.4 billion was spent on damage to motor vehicles as a result of collisions related to SU.
• Damage to property due to fires associated with SU was $745 million. 
Between 2015 and 2017, other direct costs increased 4.1% from $96 per person in 2015 to about $100 per 
person in 2017. 
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Implications
A substantial proportion (63.0%) of the costs of SU in 2017 were related to the use of alcohol and tobacco. 
Tobacco was by far the deadliest substance, accounting for 47,707 deaths in 2017. Although tobacco use 
accounted for more deaths, alcohol use led the way in total costs. 
The higher costs associated with alcohol use can be attributed to injuries and deaths of people at a younger 
age, and was therefore responsible for more lost years of productive life. In contrast to tobacco, costs 
related to alcohol use are rising. This rise in alcohol-related costs and decrease in tobacco-related costs is 
hardly surprising. While we have been reaping the benefits of strong public-health policies designed to curb 
tobacco use, this has not been the case for alcohol. It is well established that increased availability of alcohol 
is associated with increased consumption. Yet some provincial and territorial governments have substantially 
loosened restrictions on the sale and availability of alcohol. Furthermore, our national advertising codes have not 
been updated in a quarter of a century. Of particular concern is that these codes do not apply to modern digital 
media, which many young people use to communicate. These factors may be contributing to rising costs and 
harms related to alcohol use. With the arrival of COVID-19, there are signs that alcohol consumption is increasing 
due to a lack of regular schedule, stress and boredom (Nanos Research, 2020). These findings suggest there will 
likely be more alcohol-attributable harms in future estimates. 
In 2017, Canada was in the midst of the opioid epidemic. As expected, the increase in opioid-related harms was 
accompanied by a substantial increase in the associated costs of opioid use. Given that the number of opioid-
related deaths increased in Canada between 2017 and 2018 (Special Advisory Committee on the Epidemic of 
Opioid Overdoses, 2020), we expect an increase in opioid-related costs and harms in future estimates.
Another key emerging finding is the rapid rise in harms associated with the use of cocaine and other CNS 
stimulants. These increases are thought to be largely attributable to increases in methamphetamine use and 
harms (Canadian Centre on Substance Use and Addiction, 2018; Canadian Community Epidemiology Network 
on Drug Use, 2019). These harms may be exacerbated by the intentional or unintentional use of stimulants with 
other harmful substances, such as fentanyl and its analogues, benzodiazepines or synthetic cannabinoids found 
in the illegal, unregulated and toxic drug supply (Canadian Community Epidemiology Network on Drug Use, 
2019; Payer et al, 2020). 
Conclusions
The estimates in this report give us a picture of the costs and harms associated with SU in Canada. They are a 
baseline against which to monitor the impacts of current and future policies designed to limit harms from SU in 
Canada. 
We are in a critical period for Canadian policy making about SU. Researchers and lawmakers are assessing the 
impacts of legal, non-medical cannabis. The nation is still in the midst of an opioid epidemic, many regions are 
experiencing increases in methamphetamine-related harms, and in the early months of 2020, the world was hit 
by a pandemic that significantly changed our social landscape. It is unclear what the full impact of these major 
social changes will be on SU in Canada. 
Throughout this crucial time, Canadian policy makers must prioritize policies to reduce harms from the legal 
substances that we take for granted yet have disproportionately large negative impacts on public health. We need 
to take a long, hard look at the varying impacts of different types of psychoactive substances on health, crime and 
productivity, and design regulatory systems that create appropriate access to substances while limiting harms. 
This report provides evidence upon which to base SU policies and against which to measure their success.
Introduction
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6 Referred to in this report as other CNS depressants.
7 Referred to in this report as other CNS stimulants.
Introduction 
This report presents estimates of the overall costs of substance use (SU) in Canada. These estimates 
are based on the most reliable, up-to-date data sources and methods available for the years 2015 to 
2017, the most recent year for which comprehensive data were available. This report is intended for 
policy makers, researchers and all Canadians who want to better understand the costs and harms of 
SU in Canada. 
Though this report is an update to Canadian Substance Use Costs and Harms 2007–2014, which was 
released in June 2018 (Canadian Substance Use Costs and Harms Scientific Working Group, 2018), 
estimates presented in this report should not be directly compared with estimates presented in the 
2007–2014 report. As we developed the 2015–2017 estimates, we improved our methodology in several 
ways. Most notably, we refined the methods we use to estimate the prevalence of SU and calculate 
poisoning deaths attributable to SU. 
The data included in this report, as well as the 2007–2014 data, are available in our online data 
visualization tool (https://csuch.ca/explore-the-data). Policy makers, researchers and interested 
Canadians can use the tool to explore the results by province and territory, year, substance, type of 
harm, cost type, sex, age group and health condition. As we apply new methods to derive updated 
estimates for 2007 to 2014, they will be made available in this tool. 
As in the previous report, this report presents estimates of the costs associated with a broad 
range of substances, including alcohol, tobacco, cannabis, opioids, central nervous system (CNS) 
depressants (excluding alcohol and opioids)6 such as benzodiazepines and barbiturates, cocaine, 
CNS stimulants (excluding cocaine)7 such as amphetamine and methamphetamine, and other 
substances (e.g., hallucinogens, inhalants). Estimates are also presented by province or territory 
and cost type (i.e., healthcare, productivity, criminal justice and other direct costs). 
Detailed methods are provided in the Canadian Substance Use Costs and Harms: Technical Report, 
available on the project website.
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Overall Costs of Substance Use in Canada 
In 2017, the overall cost of SU in Canada was estimated to be $46.0 billion.8 This estimate represents a cost 
of about $1,258 per person in Canada. In 2017, the legally available9 and most widely used psychoactive 
substances — alcohol and tobacco — accounted for almost 63% of these costs. Alcohol accounted for about 
$16.6 billion (36.2%), tobacco accounted for about $12.3 billion (26.7%) and other substances accounted for 
about $17.1 billion (37%). Among the other substances studied, opioids accounted for the highest costs, followed 
by cocaine (see Figure 1 and Table 1). 
Figure 1. Costs (in billions) and percentage of total costs attributable to substance use in Canada by substance 
and cost type, 2017
8 This number does not include costs associated with inpatient hospitalizations, day surgeries or emergency department visits in 
Quebec. A rough calculation based on per-person costs in Ontario across these three cost types indicates that these costs account for 
about $857 million or 1.9%. The 2017 estimates do not include costs associated with lost productivity due to premature deaths in Yukon 
territory. This led to an underestimation of approximately $103 million or 0.2% of total cost based on a similar calculation using Northwest 
Territories per person premature death costs. All estimates as well as per-person estimates should be considered conservative by this 
margin ($960 million or 2.1% in total). 
9 For the purposes of this report, legal substances refer to substances that were legally available for recreational use during the reporting 
period (alcohol and tobacco). Costs and harms associated with other substances could be linked to legal use (e.g., an individual taking 
opioid medication as prescribed may still experience harm). 
Note: These estimates do not include costs associated with inpatient hospitalizations, day surgeries or emergency department 
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Cost estimates included in this report are broken down into four major cost types: 
Healthcare costs associated with inpatient hospitalizations, day surgeries, emergency department 
visits, specialized treatment for SU disorders, physician time and prescription drugs; 
Lost productivity costs associated with SU-attributable premature deaths, long-term disability and 
short-term disability (absenteeism and impaired performance on the job, or “presenteeism”);
Criminal justice costs associated with policing, courts and correctional services (admissions to 
sentenced custody) attributable to SU, including costs associated with the enforcement of current 
drug and impaired-driving laws, as well as the impact of violent and non-violent crimes that would not 
have occurred without some SU; and
Other direct costs, a mixed category that includes costs associated with the federal funding of 
research and prevention programs, fire damage and motor vehicle damage attributable to SU, drug 
testing in the workplace, employee-assistance programs and workers’ compensation. 
The costs of SU in Canada in 2017 by cost type are presented in Figure 2 and Table 1. Productivity losses 
were $20.0 billion or 43.5% of the total costs, while healthcare costs were $13.1 billion (28.4%). The third-
highest contributor to the total costs related to SU were criminal justice costs, which were $9.2 billion or 
20.1% of the total.
Figure 2. Overall costs (in billions) and percentage of total overall costs attributable to substance use in 
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Table 1. Costs attributable to substance use in Canada (in millions of dollars), 2017









Healthcare costs 5,432.5 6,149.9 322.0 438.6 308.9 150.3 241.1 22.7 13,066.1
Inpatient 
hospitalizations                   
1,343.9 1,561.2 63.9 91.7 71.4 31.6 38.5 4.5 3,206.6
Day surgery 63.2 58.4 1.1 0.3 0.5 0.3 0.2 0.0 124.1
Emergency 
department visits
234.9 115.2 16.2 21.8 14.7 8.6 11.4 1.5 424.3
Specialized SU 
treatment
488.1 0.0 61.7 48.5 10.1 24.2 67.5 2.3 702.3
Physician time 1,908.6 2,457.4 105.6 162.2 123.7 50.8 73.3 8.6 4,890.1
Prescription drugs 1,393.7 1,957.8 73.4 114.1 88.5 34.8 50.3 5.9 3,718.6
Lost productivity 
costs
6,740.1 5,893.3 547.2 4,246.6 590.7 983.5 916.4 100.5 20,018.3
Premature death 4,632.1 2,836.7 362.6 3,913.1 320.1 905.0 802.8 48.7 13,821.2




662.3 1,270.2 93.6 177.3 150.6 24.2 38.5 44.4 2,460.9
Criminal justice 
costs
2,792.4 5.4 1,620.3 944.9 360.9 2,565.9 800.1 152.1 9,242.0
Policing 1,489.8 0.0 844.5 551.1 204.4 1,507.7 458.4 90.2 5,146.1
Courts 575.5 0.0 308.7 173.5 66.4 471.4 146.2 25.7 1,767.4
Correctional services 727.1 0.0 467.1 220.3 90.1 586.8 195.5 36.2 2,323.0
Other direct costs 1,659.9 234.9 750.9 320.3 599.5 13.4 20.5 50.4 3,649.9
Research and 
prevention 
101.5 58.7 20.0 21.2 16.2 3.2 4.3 25.1 250.1
Fire damage 553.4 176.2 15.4 0.0 0.0 0.0 0.0 0.0 745.0
Motor vehicle 
damage
867.5 0.0 672.5 272.3 551.7 8.6 12.1 23.6 2,408.4
Workplace drug 
testing
8.7 0.0 7.4 7.9 5.7 0.6 1.0 0.6 31.8
Employee-
assistance programs




74.3 0.0 31.4 13.7 25.0 0.4 0.6 1.1 146.5
Total 16,625.0 12,283.5 3,240.4 5,950.4 1,859.9 3,713.0 1,978.1 325.7 45,976.2
Total cost per 
person (in dollars)
454.86 336.14 88.64 162.81 50.89 101.55 54.12 8.91 1,257.92
% of all SU-related 
costs
36.2% 26.7% 7.0% 12.9% 4.0% 8.1% 4.3% 0.7% 100% 
Note: These estimates do not include costs associated with inpatient hospitalizations, day surgeries or emergency department visits in Quebec. 
At the time of this report, the data on premature deaths in Yukon (2017 only) required to calculate costs of potential years of productive life lost 
were not available from Statistics Canada’s Vital Statistics database
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In 2017, the per-person costs of SU were highest in the territories. This finding reflects higher rates of alcohol 
and tobacco use in the territories, as well as the higher costs of healthcare for territorial residents (see Figure 3). 
Figure 3. Per-person costs attributable to substance use by province and territory, 2017
Note: Meaningful per-person costs for Quebec and Yukon could not be calculated. The estimated per-person costs in Canada 
should be considered an underestimate, as they do not include costs associated with inpatient hospitalizations, day surgeries or 
emergency department visits in Quebec, nor costs associated with lost productivity due to premature deaths in Yukon.
Cost Trends from 2015 to 2017
The cost of SU in Canada increased almost 6% from $43.5 billion in 2015 to $46.0 billion in 2017. However, 
the Canadian population also increased over that time. The per-person costs of SU in Canada increased by 
3.3% from $1,218 per person in 2015 to $1,258 in 2017 (in 2017 inflation-adjusted Canadian dollars).
From 2015 to 2017, the largest per-person increases in cost were associated with the use of opioids and CNS 
stimulants (excluding cocaine). Costs associated with opioid use grew by 20.9% from $135 to $163, while 
costs associated with CNS stimulants increased by 22.1% from $44 to $54 (see Figure 4). 
In addition to these large increases, the per-person costs associated with alcohol use increased 1.6% from 
$448 per person in 2015 to $455 per person in 2017. Other per-person cost increases were associated with 
cocaine (10.5%), CNS depressants (4.1%) and cannabis (2.4%). The sizeable increases in costs associated 
with both opioids and CNS stimulants were expected given the opioid crisis in most parts of Canada and the 
more recent increase in harms related to the use of methamphetamines. The costs associated with tobacco 
use decreased (5.1%) from $354 per person in 2015 to $336 per person in 2017. These decreases are largely 
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Figure 4. Per-person costs attributable to substance use in Canada by substance, 2015–2017
Note: These estimates do not include costs associated with inpatient hospitalizations, day surgeries or visits to emergency 
departments in Quebec, nor costs (for 2017 only) associated with lost productivity due to premature deaths in Yukon. Therefore, costs 
are likely 2.1% higher than what is reported here. 
Overview of Methods
The methods we used in this project were based on the approaches applied in other Canadian and international 
cost studies on SU (e.g., Rehm et al., 2006; Collins & Lapsley, 2008). However, the availability of additional 
datasets and analytic resources enabled us to significantly improve and refine our methods across a number 
of key areas. As a result, the estimates presented in this report should not be directly compared to those 
made in earlier Canadian cost studies.
All dollar estimates are presented in 2017 Canadian dollars. The national Consumer Price Index was used to 
adjust costs from earlier years to 2017 dollars (Statistics Canada, 2018e). Results presented in this report are 
also presented by calendar year. When data were only available by fiscal year (FY), we converted them into 
calendar year by allocating 25.0% of the costs and counts to the following year. For example, when converting 
FY 2016–2017 to calendar years 2016 and 2017, we added 25.0% of FY 2015–2016 to 2016, 25.0% of FY 
2016–2017 to 2017, and so on.
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Wherever possible, we used current data and data specific to the provinces and territories first to estimate 
relevant harms from SU that might generate costs. For example, many hospitalizations caused by SU are 
clearly identified in official diagnostic records (e.g., opioid overdose, SU disorder, alcoholic psychosis). We 
were able to access individual-level data on the costs of different types of hospitalizations and then combine 
these data to calculate accurate costs for hospitalizations that are 100% attributable to SU. However, many 
health conditions and crimes are only partially attributable to SU. Healthcare and crime records cannot 
always reliably record the contributions of SU and so an indirect attributable fraction approach was used 
to estimate the proportions of health and crime outcomes that could be considered caused by alcohol or 
other SU. 
The Attributable Fraction Approach
There are some health conditions and crimes that, by definition, can be fully attributed to SU. For example, 
all hospital stays associated with an International Statistical Classification of Diseases and Related Health 
Problems (ICD) code of “mental and behavioural disorders attributed to the use of alcohol”10 are caused by 
alcohol use. Similarly, all charges associated with a violation of the Controlled Drugs and Substances Act for 
cocaine possession can be fully attributed to cocaine use. However, healthcare and crime records do not 
always record the contributions of SU. 
For example, an association between specific levels of alcohol consumption and colorectal cancer has 
been established (World Health Organization, 2014). However, not all cases of colorectal cancer are caused 
by alcohol use. The attributable fraction approach allows us to estimate the number of cases of colorectal 
cancer in the population that can be attributed to alcohol use. To do so, we assess the risk of developing a 
condition (in this case, colorectal cancer) that is associated with various quantities of alcohol consumption 
and the proportion of people in a population consuming alcohol at those quantities. Using this information, 
we can estimate the proportion of all cases of colorectal cancer attributable to alcohol use. Multiplying this 
proportion by the total number of colorectal cancer cases allows us to calculate the number of alcohol-
attributable cases of colorectal cancer and the costs associated with treating them. This procedure can then 
be conducted for all the conditions for which alcohol is causally associated. 
The causal associations for all included conditions were based on analyses by the U.S.-based Centers 
for Disease Control and Prevention (2008) and the World Health Organization (2014). First, we found that 
there are 46 alcohol-attributable conditions (see Table 2). We then conducted a similar exercise for other 
substances. A list of substances, as well as the health conditions considered fully and partially attributable, 
are included in Table 2. 
The healthcare and lost productivity estimates were mostly completed using a condition-based, 
epidemiological attributable fraction approach. In this approach, the proportion of each condition related to 
SU that would be eliminated in the absence of SU was calculated. These proportions were used to estimate 
the healthcare and lost productivity costs incurred within a given year. 
For more details about the attributable fraction approach and how it was applied in estimating the different 
costs, see the technical report. 
10 When patients are discharged from hospitals in Canada, they are assigned a code indicating the main reason for their hospital stay. 
The coding systems used differ depending on the database. The Discharge Abstract Database and Hospital Morbidity Database use 
the Canadian enhancement of the International Statistical Classification of Diseases and Related Health Problems, 10th Revision (ICD-
10-CA; Canadian Institute for Health Information, 2001) to code the diagnosis of the hospital stay.
Canadian Substance Use Costs and Harms 2015–201714
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Methodological Differences from CSUCH 2007–2014
The methods we used to calculate the costs of SU in Canada from 2015 to 2017 are almost the same as the 
ones we used in our 2007–2014 report. These methods are described in detail in the technical report. 
However, in calculating our estimates for 2015 to 2017, we improved our methods to model SU prevalence 
and to estimate SU-attributable poisoning deaths. As a result, estimates presented in this report should not 
be directly compared with estimates in the 2007–2014 report. The cost and harm estimates described in this 
report, as well those from 2007 to 2014, are available in our online data visualization tool (https://csuch.ca/
explore-the-data). As we apply new methods to update the estimates for 2007 to 2014, we will make them 
available in this tool. Specific changes to the methods are described in the relevant sections below. 
Substance Use 
Prevalence Estimates
Canadian Substance Use Costs and Harms 2015–2017
Canadian Centre on Substance Use and Addiction 
17
11 ICD-10 codes F10–F15 and T40 codes
Substance Use Prevalence Estimates
Most of the methods we used to calculate the estimates in this report required estimates of the prevalence of 
SU in Canada by province or territory, age, sex, year and type of substance. We drew upon multiple national, 
provincial and territorial surveys that included questions on SU (see Table 3). Some of the required data elements 
had either insufficient or missing data. Fortunately, we were able to find predictable trends by province or 
territory, age, sex, year and type of substance within the very large survey datasets available. These consistent 
trends helped us model and accurately estimate the prevalence of SU where direct survey estimates were 
unavailable. 
More detailed descriptions of the methods used to model these detailed prevalence estimates are included in the 
technical report. For estimates related to alcohol and tobacco use, survey data were complemented with retail 
sales data by province, territory and year. For all the substances, survey data were complemented with counts of 
hospitalizations by province, territory and year that are wholly attributable to each substance category.11
Methodological Differences from CSUCH 2007–2014
When we modelled the prevalence estimates for 2007 to 2014, we did not use data from the Discharge Abstract 
Database that includes the number of hospitalizations for mental and behavioural disorders wholly attributable to 
each substance and the number of hospitalizations due to SU poisonings. The addition of these new data added 
substantial power to our analytic estimates as they harness relatively large, routinely collected sets of data from 
each province and territory, for each SU category, each year and by age and sex. 
Table 3. Data sources used to model prevalence estimates
Substance Data Sources
Alcohol Canadian Alcohol and Drug Use Monitoring Survey (CADUMS) 2008–2012 
(Statistics Canada, 2017a, 2017b, 2017c, 2017d, 2017e); CTADS 2013, 2015 
and 2017 (Statistics Canada, 2017o, 2017p, 2019d); Canadian Community 
Health Survey (CCHS) 2005 and 2007–2014 (Statistics Canada, 2017f, 
2017g, 2017h, 2017i, 2017j, 2017k, 2017l, 2017m, 2017n); official sales from 
Statistics Canada 2006–2017 (Statistics Canada, 2019k)
Tobacco CADUMS 2008–2012 (Statistics Canada, 2017a, 2017b, 2017c, 2017d, 
2017e); Canadian Tobacco, Alcohol and Drugs Survey (CTADS) 2013, 2015 
and 2017 (Statistics Canada, 2017o, 2017p, 2019d); CCHS 2005 and 2007–
2014 (2017f, 2017g, 2017h, 2017i, 2017j, 2017k, 2017l, 2017m, 2017n); 
official sales from Statistics Canada 2006–2017 (Statistics Canada, 2019h)
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cocaine, other CNS 
stimulants and 
other substances 
CADUMS 2008–2012 (Statistics Canada, 2017a, 2017b, 2017c, 2017d, 
2017e); CTADS 2013, 2015 and 2017 (Statistics Canada, 2017o, 2017p, 
2019d); Northwest Territories Substance Use and Addictions Survey 2012 
(Northwest Territories Health and Social Services, 2017)
All substances CIHI: Discharge Abstract Database 2006–2007 to 2017–2018 (Canadian 
Institute for Health Information, 2017a, 2017b, 2017c, 2017d, 2017e, 2017f, 
2017g, 2017h, 2017i, 2019a, 2019b, 2019c)
Results
The prevalence of Canadians using tobacco decreased by 1.3% between 2015 and 2017 (see Table 4).  
We also observed a steady decline in the use of opioids over the past 12 months during the project 
period (almost a 2.0% decrease), while the use of other CNS depressants increased by 1.5%. 
Cannabis use increased from 11.8% in 2015 to 13.8% in 2017. The use of CNS stimulants grew 
marginally overall, with greater increases among people of different ages, sexes and regions. For 
instance, in 2015, 5.3% of males aged 15 to 34 reported using CNS stimulants (excluding cocaine) in 
the past year, increasing to 10.9% in 2017. 
Table 4. Estimates of substance use prevalence in Canada by substance, 2015–2017 (percent of 
population using substance in past year)
Substance 2015 2016 2017
Alcohol 76.9 77.0 77.1
Tobacco 14.3 13.7 13.0
Cannabis 11.8 13.2 13.8
Opioids 13.6 12.6 11.7
Other CNS depressants 10.8 11.6 12.3
Cocaine 1.9 1.9 2.0
Other CNS stimulants 2.7 3.1 3.1
Other substances 2.3 2.1 2.1
Note: Estimates for alcohol and tobacco refer to the prevalence of people who currently drink (individuals who have consumed 
at least one standard drink of alcohol in the past year) and people who currently smoke (individuals who have smoked at least 
100 cigarettes in their lifetime and at least one in last year). The estimates presented above are aggregated across age and sex 
groups and regions. The more detailed data show greater variation in prevalence between age and sex groups. For prevalence 
estimates by region, age and sex groups, see the technical report. 
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Limitations
There are limited data available to supplement the survey data. This is particularly true for illegal and “other 
substances” categories, which might have affected the reliability of the exposure estimates. The inclusion of 
the hospitalization data for 100% SU-attributable conditions has improved the accuracy of the 2015–2017 
estimates compared to the 2007–2014 estimates (Canadian Substance Use Costs and Harms Scientific 
Working Group, 2018). 
We continue to model prevalence estimates for substances other than alcohol, tobacco and cannabis for 
the territories with limited territory-specific survey data. We used population data from the territories and 
highly consistent patterns in the survey data from the provinces to estimate the extent of SU in the territories. 
Counts of conditions that are 100% attributable to SU were used to improve the accuracy of territorial and 
provincial estimates. 
To estimate the instances of HIV, viral hepatitis B and viral hepatitis C attributable to substance use requires a 
unique methodology, as the causal pathway for these conditions is through injection drug use (IDU) only, and 
not any substance use. The survey sources used in this report do not separate IDU into substance categories. 
Because of this lack of information, the relative weighting between substances that can be injected (opioids, 
cocaine and other CNS stimulants) was used to divide the overall attributable fraction derived from IDU 
prevalence in each region, year, gender and age group. 
The prevalence of heroin use was used to represent the opioid portion of IDU. We note that this may 
have resulted in a significant underestimation of the number of instances of HIV, viral hepatitis B and viral 
hepatitis C attributable to opioids, and misallocation of the remaining weights to other substances. A post 
hoc sensitivity analysis showed that this methodological approach resulted in a maximum underestimation 
of 0.28% of total inpatient hospitalizations attributable to opioids in 2015, with smaller impacts across 
other study years and substances. The overall impact of these three conditions, as compared to the total 
aggregations in this report, is small. The estimates for these health conditions should be treated with caution, 
and opioid prevalence will be used in the place of heroin prevalence in the next iteration of this report.
Healthcare Costs
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Healthcare Costs
Cost estimates are provided for inpatient hospitalizations, day surgeries, emergency department visits, 
specialized treatment for SU disorders, physician time and prescription drugs. Fundamental to these 
estimates is the use of the attributable fraction approach for estimating the proportions of different 
types of illness or injury that can be attributed to the use of a particular substance. Attributable fractions 
were calculated using the latest World Health Organization methodologies to assess burden of disease 
(Degenhardt et al., 2016) and a new international open-access resource, the International Model of Alcohol 
Harms and Policies, for alcohol-attributable fractions (Sherk et al., 2017, Sherk et al., 2020). 
The diagnostic information available for hospitalizations is the most reliable and detailed. We were able to 
access individual-level data on the costs of different types of hospital admissions for conditions that are 
100% attributable to SU and conditions that are partially attributable to SU. We then combined these data to 
come up with accurate cost estimates for all health conditions related to SU. This information was used as 
a basis for estimating SU-attributable healthcare costs in other domains as well. A list of health conditions 
considered either 100% or partially attributable to SU are displayed in Table 2. The data sources used to 
develop the healthcare cost estimates are listed in Table 5. 
Methodological Differences from CSUCH 2007–2014
The methods we used to calculate healthcare costs and harms for 2015 to 2017 were largely the same as 
the ones we used for 2007 to 2014, with the exception of one minor improvement: a change to the ICD-10 
codes included in the “other substances” category. For the 2015–2017 update, we only included discharges 
that had a T-code (injury, poisoning, certain other consequences of external causes) associated with one of 
the substance categories. This change reduced the count of inpatient hospitalizations, day surgeries and 
emergency department visits attributed to the “other substances” category. 
For full details of the methods used, see the technical report.
Table 5. Data sources used to calculate costs of healthcare related to substance use
Costs/Harm Data Source
SU attributable fractions Alcohol: Calculated using the International Model of Alcohol Harms and 
Policies (Sherk et al., 2017; Sherk et al., 2020)
Tobacco: Relative risks taken from the U.S. Surgeon General’s report 
(National Center for Chronic Disease Prevention and Health Promotion, 
2014)
Other substances: Various relative risks taken from the literature on 
specific conditions (see technical report)
Inpatient hospitalizations CIHI: Discharge Abstract Database 2006–2007 to 2017–2018 (Canadian 
Institute for Health Information, 2017a, 2017b, 2017c, 2017d, 2017e, 
2017f, 2017g, 2017h, 2017i, 2019a, 2019b, 2019c)
CIHI: Cost of a Standard Hospital Stay (indicator) (Canadian Institute for 
Health Information, 2019d)
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Day surgeries CIHI: Discharge Abstract Database 2006–2007 to 2017–2018 (Canadian 
Institute for Health Information, 2017a, 2017b, 2017c, 2017d, 2017e, 
2017f, 2017g, 2017h, 2017i, 2019a, 2019b, 2019c) and National 
Ambulatory Care Reporting System (NACRS) 2006–2007 to 2017–2018 
(Canadian Institute for Health Information, 2017j, 2017k, 2017l, 201  7m, 
2017n, 2017o, 2017p, 2017q, 2017q, 2017r, 2019e, 2019f, 2019g)
CIHI: Cost of a Standard Hospital Stay (indicator) (Canadian Institute for 
Health Information, 2019d)
Emergency department visits CIHI: NACRS 2006–2007 to 2017–2018 (counts) (Canadian Institute for 
Health Information, 2017j, 2017k, 2017l, 2017m, 2017n, 2017o, 2017p, 
2017q, 2017q, 2017r, 2019e, 2019f, 2019g)
CIHI: Cost of a Standard Hospital Stay (indicator) (Canadian Institute for 
Health Information, 2019d)
Specialized treatment for SU 
disorders
National Treatment Indicator (NTI) Working Group data 2009–2010 to 
2015–2016 (counts) (Beasley, Jesseman, Patton, & National Treatment 
Indicators Working Group, 2012; McQuaid, Di Gioacchino, & National 
Treatment Indicators Working Group, 2017; Meister, Maloney-Hall, 
Urbanoski, & National Treatment Indicators Working Group, 2018; Pirie, 
Jesseman, Di Gioacchino, & National Treatment Indicators Working 
Group, 2014; Pirie, Jesseman, & National Treatment Indicators Working 
Group, 2013; Pirie & National Treatment Indicators Working Group, 
2015; Pirie, Wallingford, Di Gioacchino, McQuaid, & National Treatment 
Indicators Working Group, 2016)
CIHI: Discharge Abstract Database 2006–2007 to 2017–2018 (Canadian 
Institute for Health Information, 2017a, 2017b, 2017c, 2017d, 2017e, 
2017f, 2017g, 2017h, 2017i, 2019a, 2019b, 2019c) and Cost of a 
Standard Hospital Stay (costs) (Canadian Institute for Health Information, 
2019d)
Literature: Comorbid mental disorders among clients in addiction 
treatment: the costs of care (costs) (Urbanoski, Rehm, Lange, & Popova, 
2014)
Physician time CIHI: National Physician Database 2006–2007 to 2017–2018 (Canadian 
Institute for Health Information, 2019h) and Quick Stats Inpatient 
Hospitalizations 2007–2017 (Canadian Institute for Health Information, 
2018)
Prescription drugs CIHI: National Health Expenditure Trends 2007–2017 (Canadian Institute 
for Health Information, 2019i)
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Results
In 2017, SU-attributable healthcare costs were $13.1 billion. Costs associated with the use of alcohol and 
tobacco (the substances legally available at the time) were estimated to account for about 89% of all SU-
attributable healthcare costs (see Figure 5). These costs are broken down by cost type and by substance 
(see Table 1). 
Figure 5. Costs (in billions) of healthcare related to substance use in Canada by substance, 2017
Note: These estimates do not include costs associated with inpatient hospitalizations, day surgeries and emergency department 
visits in Quebec. A rough calculation based on Ontario per-person costs and data available from Quebec suggests that these per-
person costs are likely conservative by about 8%.
Estimated costs by province or territory are largely driven by population size; the smaller the population, 
the higher the costs. Direct comparisons can be made from the data in Figure 6, which presents estimated 
healthcare costs attributable to SU per person. These estimates show that for all of Canada (excluding 
Quebec), healthcare costs attributable to SU were $386 per person in 2017. Per-person costs were highest in 
the territories and relatively high in Atlantic Canada. 
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Figure 6. Per-person costs of healthcare related to substance use in Canada (except Quebec) by province and 
territory, 2017
Note: Meaningful per-person costs for Quebec could not be calculated.
As shown in Table 6, contributing to these costs were the estimated 277,060 hospitalizations attributable to SU, of 
which 141,271 were from tobacco use and 105,065 from alcohol. By comparison, opioid-attributable hospitalizations 
were estimated to be the next-highest category with almost 9,327 hospital stays.






Other CNS depressants 6,915 
Cocaine 2,965 
Other CNS stimulants 4,896 
Other substances 522 
Total 277,060
Canada’s overall per-person healthcare costs related to substance use increased almost 3% from $348 in 2015 to 
$35812 in 2017. More specifically, over this time period:
• Per-person healthcare costs related to alcohol use increased almost 4.8% from $142 to $149, and 
tobacco use decreased 2.2% from $172 to $168 (see Figure 7). 
• Costs associated with cannabis use increased 20.8% from about $7 per person to $9 per person.







































13 Only some healthcare-related data were available for Quebec. These national per-person trend estimates include Quebec and therefore 
differ from the $386 indicated above.
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Large increases in per-person costs were also noted across many other substance categories:
• Per-person healthcare costs associated with opioid use increased 11.5% from about $11 to $12, 
and costs associated with the use of other CNS depressants increased 15.8% from about $7 to $8.
• Per-person healthcare costs associated with cocaine use increased 19.8% from about $3 to $4, 
and associated with the use of other CNS stimulants increased 37.3% from about $5 to $7  
(see Figure 7). 
Figure 7. Per-person healthcare costs related to substance use in Canada by substance, 2015–2017
Note: These estimates do not include costs associated with inpatient hospitalizations, day surgeries and emergency department 
visits in Quebec. A rough calculation based on Ontario per-person costs and data available from Quebec suggests that these 
per-person costs are likely conservative by about 8%.
Limitations
The methodology we used to assess the burden of disease assumes that high-quality studies from around 
the world on the association between exposure to substances in a population and disease and injury are 
universally applicable. While we used national, provincial and territorial data to assess the prevalence of broad 
categories of disease and injury and population exposure to SU, we must use international assumptions about 
the relationship between SU and the risk of some diseases and injuries, as these data rarely exist for a single 
country. As is standard practice in SU epidemiology, we have relied on the latest systematic reviews and meta-
analyses of the international literature to estimate these risk relationships. The evidence base of published 
studies, however, is stronger in some areas than in others. In general, the published literature is stronger in 
relation to tobacco and alcohol use, and weaker for most of the other substances. 
To estimate inpatient hospitalizations, day surgeries and emergency department visits, we applied attributable 
fractions to individual-level data. However, to estimate the costs of physician time and prescription drugs, 
we used an attributable percentage methodology.13 Using this method, we assume that the proportional 
contributions of different types of substances to healthcare costs are consistent. We will investigate this 
assumption and continue to refine our methodologies to improve the accuracy of our estimates. 
13 Attributable percentages are equivalent to the percentage of total inpatient hospitalizations that could be attributed to substance use-
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Lost Productivity Costs 
Estimates are provided for the indirect costs associated with lost productivity related to SU in terms of 
foregone earnings. These costs are due to premature death, long-term disability and short-term disability 
(absenteeism and presenteeism). 
To estimate lost productivity costs due to premature death, we primarily used the human capital approach 
(Single et al., 2003). This approach assumes the deceased individual cannot be replaced in the workforce and 
that their lost income up to the age of retirement (assumed to be 65 years) is not recoverable. To determine the 
number of deaths attributable to SU, we used the same condition-based, epidemiological attributable fraction 
approach we used to assess healthcare costs related to SU. To estimate the cost of long-term disability, we 
limited our estimates to the year in question as recommended by Schroeder (2012). The methods used to 
calculate lost production costs are described in detail in (Sorge et al., 2019) and in the technical report. 
Methods Used to Estimate Deaths Attributable  
to Substance Use Poisoning 
For our estimates of deaths attributable to substance poisoning, we relied on the Canadian Vital Statistics 
database and the assistance of and collaboration with Statistics Canada (Centre for Population Health Data unit). 
In the Vital Statistics database, each SU-attributable poisoning death is identified as either accidental (with 
codes beginning with X4* or Y1*) or intentional (with codes beginning with X6*). Also included on the record 
is a list of codes identifying the substances considered to be contributing to the death. For records in which 
one substance was identified as contributing to the death, we assigned the record to that substance category. 
For records in which multiple substances were indicated, we created drug poisoning weights. We used these 
weights to distribute deaths attributable to polysubstance use14 based on the relative proportions of SU-
attributable deaths in which only one substance was considered a contributor. 
For example, if we found 100 deaths to which alcohol and opioids were considered to have contributed, we 
looked at the ratio of deaths attributable to alcohol use only to deaths attributable to opioid use only and 
distributed the 100 deaths accordingly. If this ratio were 6:4, we allocated 0.6 of each of the 100 deaths to 
alcohol use and 0.4 to opioid use. We repeated this procedure for all of the polysubstance combinations in 
the data. The final poisoning weights were adjusted for age and regional variations using the corresponding 
inpatient hospitalization proportions for substance poisonings. 
Methods Used to Assess Long- and Short-Term Disability
For the 2007–2014 estimates, we used questions in the Canadian Community Health Survey assessing 
permanent inability to work and interference due to drugs or alcohol to assess the costs associated with long-
term disability and short-term disability (absenteeism and presenteeism). However, these questions were not 
included in the 2015 survey. As a result, we estimated absenteeism and presenteeism costs for 2015–2017 
using simple linear regression. 
We used an alternative dataset (Canada Pension Plan [CPP] disability beneficiaries) to more accurately 
estimate long-term disability costs between 2015 and 2017. Given there were two years of overlap (2012 and 
2014) between the survey and CPP datasets, we were able to adjust CPP disability counts for 2015 to 2017 to 
estimate survey counts of permanent disability by applying the average quotient of survey counts divided by 
CPP counts from the overlap years. The data sources used to develop these estimates are listed in Table 7. 
For full details on the methods used, see the technical report. 
14 For the following substance categories: alcohol, opioids, other CNS depressants, cocaine and other CNS stimulants. Cannabis 
and other psychoactive substances were excluded from this analysis due to evidence suggesting these substance categories cannot 
directly cause overdose death, or do so very rarely (Hall & Solowij, 1998). In future iterations of this project, we will further investigate the 
continued validity of excluding these substances.
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Table 7. Data sources used to calculate lost productivity costs related to substance use
Costs/Harm Data Sources
Premature death Vital Statistics – Death Database (Statistics Canada, 2017t, 2019m); 
General Social Survey (Statistics Canada, 2017q) (counts); Labour 
Force Survey (Statistics Canada, 2017s, 2019j); Job Vacancy and 
Wages Survey (Statistics Canada, 2017r; 2019i) (costs)
Long-term disability Canadian Community Health Survey (Statistics Canada, 2017f, 
2017g, 2017h, 2017i, 2017j, 2017k, 2017l, 2017m, 2017n) (counts 
and costs); Canadian Pension Plan (CPP) Disability Benefits by 




Canadian Community Health Survey (Statistics Canada, 2017f, 
2017g, 2017h, 2017i, 2017j, 2017k, 2017l, 2017m, 2017n)  
(counts and costs)
Methodological Differences from CSUCH 2007–2014
The methods described above were different than the ones used for the 2007–2014 report. For the 2007–2014 
report, we distributed the poisoning deaths into substance categories based on the inpatient hospitalization 
proportions for substance poisonings. These poisonings deaths were then combined with all partially  
SU-attributable death counts. The improved methods more accurately distribute the poisoning deaths into  
the substance categories. 
We also expanded the criteria for defining a SU-attributable death by including three new codes15 and changed 
the method we used to distribute SU-attributable poisoning deaths that involved more than one substance.
For full details of the methods used, see the technical report.  
Results
In 2017, lost productivity costs attributable to SU were over $20 billion. Costs associated with the use of 
substances legally available at the time (alcohol and tobacco) were estimated to account for slightly more than 
63% ($12.6 billion) of all lost productivity costs (see Figure 8). Of the remaining 36.9% of SU-attributable lost 
productivity costs, opioids accounted for over 57% ($4.2 billion) of the costs.
15 The three new codes are X44, accidental poisoning by and exposure to other and unspecified drugs, medications and biological 
substances; X64, intentional self-poisoning by and exposure to other and unspecified drugs, medicaments and biological substances; 
and Y14, poisoning by and exposure to other and unspecified drugs, medicaments and biological substances, undetermined intent.
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Figure 8. Costs (in billions) of lost productivity attributable to substance use in Canada by substance, 2017
Note: At the time of this report, the data on premature deaths in Yukon (2017 only) required to calculate costs of potential years of 
productive life lost were not available from Statistics Canada’s Vital Statistics database. A rough calculation based on per-person costs 
and data in the Northwest Territories suggests that these per-person costs are likely conservative by about 0.5%.
The estimated per-person lost productivity costs attributable to SU for the provinces, territories and Canada are 
presented in Figure 9. For the whole of Canada, lost productivity attributable to SU costs an average of $441 per 
person. Per-person costs were highest in the territories. 
Figure 9. Per-person lost productivity costs attributable to substance use in Canada by province and territory, 2017
Note: At the time of this report, the data on premature deaths in Yukon (2017 only) required to calculate costs of potential years of 
productive life lost were not available from Statistics Canada’s Vital Statistics database. Therefore, meaningful per-person costs for lost 
productivity could not be calculated for Yukon in 2017. 
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Overall per-person lost productivity costs increased by 4.5% from $524 in 2015 to $548 in 2017. The per-person 
costs of lost productivity due to alcohol use remained steady from 2015 to 2017 at $184, while per-person costs 
related to tobacco use decreased by over 8% (from $176 in 2015 to $161 in 2017) (see Figure 10). 
The largest increase was related to opioid use. The per-person cost of opioid use increased by more than 34% 
over the course of the project from $87 per person in 2015 to $116 per person in 2017 (see Figure 10). This 
increase is largely due to the growing number of poisoning deaths related to opioids (see Figure 11). 
Per-person lost productivity costs were higher for cocaine and other CNS stimulants. The per-person costs 
for cocaine use increased by 20.1% from $22 in 2015 to $27 in 2017, while the per-person costs for other CNS 
stimulants increased by 21.6% from $21 in 2015 to $25 in 2017. 
Figure 10. Per-person lost productivity costs attributable to substance use in Canada by substance, 2015–2017
Note: At the time of this report, the data on premature deaths in Yukon (2017 only) required to calculate costs of potential years 
of productive life lost were not available from Statistics Canada’s Vital Statistics database. These per-person costs are likely 
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Underlying these costs are the estimated numbers of deaths and the potential years of productive life lost, as 
shown in figures 11 and 12, respectively. Tobacco use was the leading cause of the 75,900 SU-attributable 
deaths with 47,707 deaths in 2017, followed by alcohol use with 18,320 deaths and opioid use with 5,084 
deaths. One measure of the economic toll of SU-attributable deaths is the total number of potential years of 
productive life lost, which are calculated up to 65 years of age. 
Alcohol was the leading contributor to the 338,555 SU-attributable potential years of productive life lost with 
113,713 in 2017. Due to the young age of many opioid-attributable deaths (mean=45.5), use of this substance 
accounted for as many as 99,836 potential years of productive life lost. 
Figure 11. Number of deaths attributable to substance use by substance, 2015–2017
Note: At the time of this report, data on premature deaths in Yukon (2017 only) were not available from Statistics Canada’s Vital 
Statistics database. 
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Figure 12. Number of potential years of productive life lost due to substance use-attributable premature deaths 
by substance, 2015–2017
Note: At the time of this report, data on premature deaths in Yukon (2017 only) were not available from Statistics Canada’s Vital 
Statistics database. 
Limitations
To meet its data confidentially requirements, Statistics Canada used a disclosure method called the Laplace 
mechanism when it provided the mortality data to the research team. This mechanism adds a random amount 
of noise to each count, which can result in negative estimations when counts are very low. While the negative 
values were left in the poisoning weights, after the weights were applied to the death counts, all negative counts 
were truncated to zero. Although this is a widely accepted solution to address negative values after application 
of the Laplace mechanism (Holohon, Braghin, Antonatos, & Aonghusa, 2018), it does result in a small positive 
bias for the final estimates. This bias likely had a greater effect on estimates for less-populous regions (e.g., the 
territories) that have low counts of premature deaths. 
In addition to this limitation, when calculating potential years of productive life lost we had to use the average 
ages of death calculated for the 2007–2014 report as Statistics Canada could not release this information due to 
privacy rules. 
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Criminal Justice Costs 
Criminal justice costs include costs associated with policing, courts and correctional services. Included in 
our calculations are expenditures for crimes that are both 100% and partially attributable to SU. The 100% 
attributable offences include impaired driving and drug-related offences that are in violation of the Controlled 
Drugs and Substances Act. These offences include the possession, trafficking and production of controlled 
substances. In addition to fully attributable crimes, we also included crimes that are partially attributable to SU. 
These include violent offences such as homicide or assault, and non-violent offences such as theft or arson. 
Attributable fractions for crimes related to SU were estimated based on a comprehensive self-report intake 
survey. This survey was given to more than 29,000 offenders as they entered federal prisons about the role 
SU played in their offences. These attributable fractions are included in the 2007–2014 report. They were 
applied to counts of partially-attributable, Criminal Code incidents (for policing costs), charges (for court 
costs) and admissions to correctional facilities (for correctional costs). The result was added to the number 
of fully attributable incidents, charges or admissions, and then divided by the total to assess the proportion 
of SU- attributable counts. The resulting proportions were then applied to the total costs associated with 
policing, court and correctional services by year and by province and territory. 
The data sources we used to develop our estimates are listed in Table 8. Details on the methods used to 
produce the criminal justice cost estimates are available in the technical report. 
Table 8. Data sources used to estimate criminal justice costs attributable to substance use
Costs/Harm Data Sources
Crime-related attributable fractions Correctional Service of Canada: Computerized Assessment 
of Substance Abuse (CASA) (Kunic and Grant, 2006); 
Women’s CASA (Correctional Service of Canada, 2017) 
Policing (crime incidents) Uniform Crime Reporting Survey 2009–2017 (Statistics 
Canada, 2019l)
Courts (charges) Integrated Criminal Court Survey 2008/09–2016/17 
(Statistics Canada, 2019h)
Correctional services  
(admissions to sentenced custody)
Adult Correctional Services 2008/09–2017/18 (Statistics 
Canada, 2019b; Statistics Canada, 2019c)
Youth Custody and Community Service Survey 2008/09–
2017/18 (Statistics Canada, 2019o)
Criminal justice costs Office of the Parliamentary Bureau Officer: Expenditure 
Analysis of Criminal Justice in Canada, 2013 (Story & Yalkin, 
2013); Canadian Centre for Justice Statistics: Policing 
Expenditures Data 2014/15–2016/2017 (Mazowita & 
Greenland, 2016; Alam & Greenland, 2017; Connor, 2018).
Tobacco Enforcement: Treasury Board of Canada Secretariat: 
Tobacco Control Strategy 2006/07–2014/15 (Treasury 
Board of Canada Secretariat, 2015); Health Canada: Federal 
Tobacco Control Strategy 2015/2016–2017/18 (Health 
Canada, 2016, 2017a, 2017b).
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Methodological Differences from CSUCH 2007–2014
We used the same methods to calculate costs related to policing, courts and correctional services for  
2015–2017 as we did to calculate the 2007–2014 estimates. The previous source for criminal justice costs 
(Story & Yalkin, 2013) only provided estimates to 2012, so we replicated the methodology used in this report in 
retrieving the 2015–2017 data from all reported sources.  
Results
In 2017, over $9.2 billion was spent on SU-attributable criminal justice costs. Costs incurred from policing crimes 
related to SU were the highest, followed by the costs of correctional services and court costs. 
Alcohol use accounted for more than 30.2% of total costs (see Figure 13). After alcohol use, cocaine use 
accounted for the second-highest costs to the criminal justice system at over $2.5 billion. Despite prevalence 
rates of less than 2% in the Canadian general population, cocaine use was associated with 24.0% of all costs 
related to violent offences and 37.4% of all costs related to non-violent offences. Policing, court and correctional 
services costs associated with violent and non-violence offences accounted for 92.0% of the criminal justice 
costs associated with cocaine use. The remaining 8.0% of costs were associated with violations of the 
Controlled Drugs and Substances Act. In contrast, 44.4% of criminal justice costs related to cannabis use were 
associated with violations of the act. 
Figure 13. Criminal justice costs (in billions) attributable to substance use in Canada by substance, 2017
The per-person criminal justice costs of SU in 2017 were $253 (see Figure 14). These costs were highest in 
Ontario and lowest in Manitoba.
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depressants























Canadian Substance Use Costs and Harms 2015–2017
Canadian Centre on Substance Use and Addiction 
37
Figure 14. Per-person criminal justice costs attributable to substance use in Canada by province and territory, 2017
Although overall per-person criminal justice costs remained relatively stable between 2015 and 2017 with just over 
a 1% increase, there were differences by substance. Per-person criminal justice costs associated with alcohol 
use decreased 2.7% from $79 in 2015 to $76 in 2017 (see Figure 15). Per-person criminal justice costs related to 
cannabis use decreased 3.4% from $46 in 2015 to $44 in 2017 (see Figure 15). During that same time, per-person 
criminal justice costs associated with cocaine use increased by 6.8% and criminal justice costs related to the use 
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Figure 15. Per-person criminal justice costs attributable to substance use in Canada by substance, 2015–2017
Limitations
Despite having relatively comprehensive data, in some cases we had to manipulate it to sort it in a way that 
permitted us to calculate estimates. For example, we needed to reorganize correctional admissions data by 
offence category (i.e., impaired driving violations, violations of the Controlled Drugs and Substances Act, violent 
and non-violent crimes). To do so, we allocated correctional admissions to the relevant offence categories 
according to the same distribution as that observed for court charges. 
In addition to distributing correctional admissions data, we also needed to impute some missing data. While 
we retrieved costing data directly from criminal justice expenditure data sources (e.g., federal and provincial 
public accounts), the detailed, itemized breakdown of expenditures required to calculate these estimates was 
only available for certain provinces and territories. Therefore, we needed to make some imputations to distribute 
costs across the provinces and territories for which there were no data. 
Criminal justice costs associated with tobacco use include costs for federal control and enforcement only. 
These costs should therefore be considered underestimates as we were unable to obtain provincial or territorial 
estimates for these costs or for other federal policing, courts and correctional services costs related to tobacco 
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Other Direct Costs
Other direct costs include estimates for expenditures related to SU across several categories. They include 
costs for research and prevention, which are considered policy costs (Single et al., 2003), and costs 
associated with fire and damage to motor vehicles. Other direct costs also include workplace costs not 
already covered in our review of lost productivity costs: costs related to employee assistance programs and 
drug testing programs, and administrative costs associated with workers’ compensation. 
Our methods to estimate SU-attributable costs varied significantly across the different categories. Some 
expenditures, such as costs associated with workplace drug testing and federal spending dedicated to SU 
research and prevention, are considered 100% attributable to SU. For other categories, such as property 
damage from fires or damage to motor vehicles damage attributable to the use of a particular substance, we 
used the attributable fraction approach to estimate the proportion of costs attributable to SU. Methods used 
for each category are described in detail in the technical report. The data sources used to develop the cost 
estimates are listed in Table 9.
Table 9. Data sources used to estimate other direct costs attributable to substance use
Costs/Harm Data Sources
Research and prevention Health Canada; Canadian Institute for Health Research; 
Heart and Stroke Foundation; Canadian Cancer Society; 
Canadian Partnership Against Cancer; Canadian Council 
for Tobacco Control; Traffic Injury Research Foundation; 
Treasury Board of Canada Secretariat: Tobacco Control 
Strategy 2006/07–2017/18 
Fire damage Provincial/territorial fire marshal and fire commissioners 
reports 2015–2017; personal communications with 
provincial/territorial fire marshals and fire commissioners
Damage to motor vehicles National Collision Database (Transport Canada, 2017) 
(counts); General Insurance Statistical Agency (2017) 
(costs)
Workplace drug-testing programs Recent Alcohol and Drug Workplace Policies in Canada: 
Considerations for the Nuclear Industry (Barbara Butler & 
Associates Inc., 2012) (counts and costs)
Employee-assistance programs Labour Force Survey 2007–2014 (Statistics Canada, 
2017s); The Prevalence and Characteristics of Employee 
Assistance, Health Promotion and Drug Testing Programs 
in Ontario (Macdonald & Wells, 1995) (counts); personal 
communications with Morneau Shepell (costs)
Workers’ compensation administrative costs Provincial/territorial workers’ compensation boards annual 
reports 2007–2017
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Methodological Differences from CSUCH 2007–2014 
We used largely the same methods for this report as we did for the 2007–2014 estimates. We used linear 
regression to substitute estimates in cases where more recent data could not be found.
Results 
In 2017, over $3.6 billion was spent on other direct costs attributable to SU. Close to half of these costs 
(45.5%) were attributable to alcohol use (see Figure 16). Cannabis use accounted for the second-highest 
proportion of other direct costs at over 20%.
Figure 16. Other direct costs (in billions) attributable to substance use in Canada by substance, 2017
The largest proportion of other direct costs was associated with damage to motor vehicles, which accounted 
for two-thirds (over $2.4 billion) of the costs. This was followed by fire damage to property, which amounted 
to $745 million in costs. 
The rates of estimated other direct costs attributable to SU per person are shown in Figure 17. In 2017, for 
Canada as a whole, about $100 per person was spent on other direct costs attributable to SU. The range in 
costs was fairly broad across the country with a low of $82 spent per person in Newfoundland and Labrador 
and a high of $242 spent per person in Nunavut.
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Figure 17. Other direct costs per person attributable to substance use in Canada by province and territory, 2017
The other direct costs per person associated with SU increased 4.1% from 2015 to 2017 (see Figure 18). Other 
direct costs per person associated with alcohol use increased 5.4% from $43 in 2015 to $45 in 2017. Other direct 
costs per person related to cannabis use increased 8.3%, from $19 in 2015 to $21 in 2017. The largest per-person 
cost increase was for other CNS stimulants at 21.7%, although other direct costs associated with this substance 
category represented less than 1% of the total costs. These yearly cost trends largely mirror those of damage to 
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Figure 18. Other direct costs per person attributable to substance use in Canada by substance, 2015–2017
Limitations
The datasets that were used to estimate other direct costs attributable to SU varied significantly. The unique 
limitations associated with each dataset are described in the technical report. In general, the SU-attributable 
other direct costs were largely accounted for by expenditures on damage to motor vehicles (66.0%) and fire 
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Discussion
In 2017, SU cost Canadians almost $46 billion. Costs associated with the use of substances legally available 
at the time (alcohol and tobacco) accounted for the majority of these costs. This fact does not diminish the 
terrible human toll of the opioid crisis gripping our country. Over 5,000 people died from opioid use in 2017, 
and across Canada significant efforts have been made to address this public health crisis. 
In addition to the impacts of opioid use, our estimates also clearly describe the impact of the reemergence 
of methamphetamine and cocaine. However, our findings indicate that when it comes to public health and 
the Canadian economy, alcohol and tobacco use cannot be ignored. These two legal substances together 
accounted for almost two-thirds of the total cost of SU and led to over 66,000 preventable deaths in 2017. 
Alcohol and Tobacco
Tobacco was by far the deadliest substance, leading to 47,707 deaths in 2017. It was followed by alcohol 
(18,320 deaths) and all other drugs combined (8,872 deaths). Although more deaths can be attributed to 
tobacco use, alcohol use led the way in total costs because it can be attributed to injuries and deaths of 
people at a younger age and was therefore responsible for more lost years of productive life. Alcohol use is 
also a contributing factor in almost 20 percent of all violent crime. 
A rise in alcohol-related costs and a decrease in tobacco-related costs is hardly surprising. While we have 
been reaping the benefits of strong public-health policies designed to curb tobacco use, this has not been 
the case for alcohol. It is well established that increased availability of alcohol is associated with higher 
consumption. Yet some provincial and territorial governments have substantially loosened restrictions on 
the sale and availability of alcohol. Furthermore, our national advertising codes have not been updated in a 
quarter of a century. Of particular concern is that these codes do not apply to modern digital media, which 
many young people use to communicate. These factors may be contributing to the increasing alcohol-related 
costs and harms. With the arrival of COVID-19, there are signs that alcohol consumption is increasing due to 
a lack of regular schedule, stress and boredom (NANOS Research, 2020), which suggests there will likely be 
more alcohol-attributable harms in future estimates.
Opioids
As expected, after alcohol and tobacco, opioid use accounted for the third-highest costs at $5.9 billion or 
12.9% of the total costs. Per-person costs also increased by 20.9% from $135 in 2015 to $163 in 2017. This 
increase was largely due to the rapid increases in lost productivity costs attributable to opioid use, which are 
largely driven by opioid-related deaths.
Estimates of opioid-related deaths presented in this report differ from those released by the Government 
of Canada. In March 2020, the Special Advisory Committee on the Epidemic of Opioid Overdoses (2020) 
released public health surveillance data with updated numbers of apparent opioid-related deaths. Estimates 
presented here are higher. For example the Government of Canada reported 3,025 deaths in 2016 and 4,144 
in 2017. In contrast, we estimated 3,944 deaths in 2016 and 5,084 in 2017. 
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Our estimates are different for several reasons:
• The counts provided by the Government of Canada only include poisoning (toxicity) 
deaths. Our estimates include poisoning as well as other partially attributable conditions, 
such as opioid-attributable infectious diseases and motor vehicle collisions. 
• The Government of Canada public health surveillance estimates include all deaths 
caused by a poisoning (intoxication/toxicity) resulting from SU, where one or more of the 
substances was an opioid. We attributed only a portion of polysubstance poisoning deaths 
involving opioids to opioids. 
• The data sources for the two updates were different. We acquired national vital statistics 
data from Statistics Canada, while the Government of Canada acquired its public health 
surveillance data from provincial and territorial offices of chief coroners or chief medical 
examiners. 
Given that the number of deaths related to opioid use remains high in 2019 (Special Advisory Committee on 
the Epidemic of Opioid Overdoses, 2020), we expect we will continue to see an increase in costs and harms 
related to opioid use in future updates of this report.
Cocaine and Other CNS Stimulants
A key emerging finding from the analyses presented is the rapid rise in harms related to the use of cocaine 
and other CNS stimulants. In 2017, costs attributable to cocaine use were $3.7 billion or 8.1% of the total 
costs. Costs attributable to the use of CNS stimulants (excluding cocaine) were $2.0 billion or 4.3% of the 
total costs. 
Per-person costs associated with use of cocaine and CNS stimulants increased dramatically. In fact, between 
2015 and 2017, per-person costs associated with the use of CNS stimulants (excluding cocaine), increased 
22.1% from $44 to $54 per person — the steepest increase of all the substances examined. These cost 
increases are thought to be largely attributable to methamphetamine use and harms (Canadian Centre on 
Substance Use and Addiction, 2018; Canadian Community Epidemiology Network on Drug Use, 2019). These 
harms are potentially exacerbated by the intentional or unintentional use of stimulants with other harmful 
substances, such as fentanyl and its analogues, benzodiazepines or synthetic cannabinoids that are present 
in the illegal, unregulated and toxic drug supply (Canadian Community Epidemiology Network on Drug Use, 
2019; Payer, Young, Mill, Maloney-Hall et al, 2020). 
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Strengths and Limitations 
Making comprehensive estimates of costs associated with health care, lost productivity, criminal justice 
and other direct costs for eight categories of substances, 13 provinces and territories and multiple years 
continues to be a substantial undertaking. Throughout this work, we used best practice methodologies and 
drew upon the most up-to-date relevant survey and administrative data sources available to us. 
Notable strengths of the project include: 
• Use of the latest World Health Organization methodologies to assess burden of disease 
(Degenhardt et al., 2016) and estimates for the contributions of SU to disease and injury as, for 
example, summarized in the new International Model of Alcohol Harms and Policies  
(Sherk et al., 2017, Sherk et al., 2020); 
• Comprehensive modelled estimates of SU prevalence by age, sex, province and territory, year 
and type of substance. These estimates incorporate data from about 150,000 Canadians who 
have completed various national, provincial and territorial surveys, as well as multiple national 
datasets on retail sales, and hospitalization data specific to SU; 
• Application of recommended modern methods for estimating impacts on lost productivity 
resulting from both long-term disability and premature death (Schroeder, 2012; see also  
Sorge et al, 2019); and 
• Use of a comprehensive survey administered to offenders when they are admitted to federal 
penitentiaries that specifically asks about the role psychoactive substances played in their 
crimes. 
Although we intended to use exactly the same methods for this report as we did for our 2007–2014 estimates, 
we were able to improve our methodologies since our previous report (Canadian Substance Use Costs 
and Harms Scientific Working Group, 2018). We felt strongly that it was important to incorporate these 
refinements to improve the accuracy of our estimates. Most notably, these included updated methods to 
estimate the prevalence of SU and poisoning deaths attributable to SU. 
While our methods have many strengths, there are also limitations and areas of uncertainty that should be 
recognized when interpreting the estimates and placing them in context. Most of these limitations have 
already been described in the relevant sections of the report. However, the following limitations apply more 
broadly. 
Reliance on Self-Reported Data
We relied extensively on self-reported data throughout the project. It is well known that self-reported levels of 
SU, particularly for illegal substances, are underestimated to some degree (Zhao, Stockwell, & MacDonald, 
2009). As a result, we have likely underestimated the prevalence of SU and associated costs. Fortunately, 
the majority (about 70%) of healthcare conditions related to illegal SU can be estimated directly from 
diagnostic data and do not need to be imputed from self-reported survey data using the attributable fraction 
methodology, so this area of uncertainty is relatively small.
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Use of Hospitalizations to Estimate Other Costs
Like Rehm and colleagues (2006), we relied heavily on estimates of the contribution of SU to hospitalizations 
given the strong and reliable data available from the Canadian Institute for Health Information. The proportional 
contributions by substance and year to hospitalizations were directly applied to other cost areas, including 
prescription drugs, specialized treatment, physician time and long-term disability. We cannot be certain, of 
course, of the extent to which these proportional contributions by different types of substance apply to these 
diverse areas of healthcare. We also inherited limitations in each of the major databases we drew upon for our 
analyses. 
Missing Costs
The list of cost categories included is not exhaustive, and the project would benefit from additional cost 
categories, such as the costs of emergency medical services and harm reduction services. In all cases, we erred 
toward including costs that could be quantified with available data and research. We will examine additional cost 
categories to determine whether to include them in future studies. While we believe we have already captured the 
majority of costs related to SU, we recognize that the addition of new cost categories could further improve our 
understanding of the costs of SU in Canada.
Despite these limitations and assumptions, we used the most up-to-date, reliable and comprehensive data and 
methods available in developing our estimates. In the future there will no doubt be better data and more research 
available that will allow us to improve our estimates (as we were able to improve on Rehm et al., 2006). Until such 
data and research become available, we feel confident that we have developed the best estimates possible.
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Conclusions
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Conclusions 
These estimates give us a picture of the costs and harms associated with SU in Canada. They are a baseline 
against which to monitor the impacts of current and future policies designed to limit harms from SU in Canada. 
For example, it is likely that the crime-related costs associated with cannabis will decrease when we update 
our data to include 2019, the first full year that non-medical cannabis was legalized. Will healthcare and other 
costs increase? Will the costs of alcohol use continue to rise as some provinces move to privatize its sale and 
distribution? Will tobacco and nicotine-related harms and costs increase or decrease as people who smoke 
switch to vapour devices for delivering nicotine? What will be the short- and long-term impact of the COVID-19 
pandemic on SU and related harms in Canada? We plan to answer these and other questions by updating our 
estimates regularly to support evidence-based decision making and efforts to reduce the costs and harms from 
SU in Canada.
We are in a critical period for Canadian policy making about SU. Researchers and lawmakers are assessing the 
impacts of legal, non-medical cannabis. The nation is still in the midst of an opioid epidemic, many regions are 
experiencing increases in harms related to the use of methamphetamines, and in the early months of 2020, the 
world was hit by a pandemic that significantly changed our social landscape. It is unclear what the full impact of 
these major social changes will be on SU in Canada. 
Throughout this crucial time, Canadian policy makers must prioritize policies to reduce harms from the legal 
substances that we take for granted yet have disproportionately large negative impacts on public health. We 
need to take a long, hard look at the varying impacts of different types of psychoactive substances on health, 
crime and productivity, and design regulatory systems that create appropriate access to substances while 
limiting harms. Canadian Substance Use Costs and Harms provides evidence upon which to base substance 
use policies and against which to measure their success.
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